<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326689</url>
  </required_header>
  <id_info>
    <org_study_id>2246-004</org_study_id>
    <nct_id>NCT01326689</nct_id>
  </id_info>
  <brief_title>A Comparative Study of KW-2246</brief_title>
  <acronym>2246-004</acronym>
  <official_title>Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and&#xD;
      safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose&#xD;
      titration in treating breakthrough pain episodes in adult cancer patients receiving strong&#xD;
      opioid analgesic on a fixed-schedule as well as rescue medication for breakthrough pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity difference</measure>
    <time_frame>30 minutes after each dose</time_frame>
    <description>Pain scores on the visual analog scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Cancer Related Pain (Breakthrough Pain)</condition>
  <arm_group>
    <arm_group_label>KW-2246</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-2246</intervention_name>
    <description>Rescue medication at an optimal dose, which is determined by dose titration</description>
    <arm_group_label>KW-2246</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Have been treated with opioid analgesic on a fixed-schedule at a stable daily dose&#xD;
&#xD;
          -  Receiving at least 1 but not more than 4 doses of rescue medication per day in average&#xD;
             and whose pain is controlled&#xD;
&#xD;
          -  ECOG PS =&lt; 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently suffered from intolerable opioid-specific adverse reactions due to opioid&#xD;
             analgesics&#xD;
&#xD;
          -  Severe respiratory dysfunction&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Severe bradyarrhythmia&#xD;
&#xD;
          -  Severe hepatic function disorder&#xD;
&#xD;
          -  Severe renal function disorder&#xD;
&#xD;
          -  Severe psychoneurotic disorder&#xD;
&#xD;
          -  Susceptibility to respiratory depression due to such conditions as increased&#xD;
             intracranial pressure, head injury or brain tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breakthrough Pain</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

